Leukoplakia of vagina
ICD-10 N89.4 ICD-11 GA14.5

Treatment of Leukoplakia of Vagina in Squamous Cell Hyperplasia of the Vulva

Clinical Scenario

Squamous cell hyperplasia of the vulva (SCHV) is one of two non-neoplastic epithelial disorders of the vulva — alongside vulvar lichen sclerosus — that are collectively referred to as vulvar leukoplakia. This page covers the management of leukoplakia of the vagina presenting in the context of this diagnosis.

Approach Overview

The initial step focuses on removing local aggravating factors: reducing irritants, substituting standard soap, avoiding urinary contact with affected tissue, and providing moisturization with emollients, alongside treatment of any co-infections. A topical corticosteroid regimen is then applied…

Full dosing schedule, sequencing, and escalation criteria available in the complete protocol.
Primary Clinical Goal
Control of genital itching

Alleviating genital itching — the predominant symptom in this condition — is the central therapeutic target guiding treatment selection and response assessment.

Instant Access to Structured Evidence-Based Regimens
References DOI: 10.5114/pm.2020.99570

Two non-neoplastic epithelial disorders of the vulva – vulvar LS (VLS) and squamous cell hyperplasia of the vulva (SCHV) – are generally referred to as vulvar leukoplakia.

The first course of action in both conditions is to minimize irritants, soap substitution, avoidance of urinary contact, moisturization with emollients, and treatment of co-infections.

Treatment of SCHV is similar and corticosteroid creams are applied. Other corticosteroids may be used in doses twice daily for several weeks and then twice weekly.

The main goal of therapy is to control genital itching, which is a major problem for the patient.

View source ↗